TRCT
BBIO icon

Tower Research Capital (TRC)’s BridgeBio Pharma BBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Buy
38,206
+23,857
+166% +$1.67M 0.07% 246
2026
Q1 		$1.07M Buy
14,349
+13,235
+1,188% +$959K 0.03% 515
2025
Q4 		$85.2K Sell
1,114
-6,424
-85% -$422K ﹤0.01% 2044
2025
Q3 		$392K Sell
7,538
-5,338
-41% -$260K 0.01% 1017
2025
Q2 		$556K Buy
12,876
+5,373
+72% +$195K 0.02% 892
2025
Q1 		$259K Sell
7,503
-13,275
-64% -$448K 0.01% 1222
2024
Q4 		$570K Buy
20,778
+18,679
+890% +$483K 0.01% 970
2024
Q3 		$53.4K Sell
2,099
-31,534
-94% -$828K ﹤0.01% 2686
2024
Q2 		$852K Buy
33,633
+32,328
+2,477% +$884K 0.01% 894
2024
Q1 		$40.4K Sell
1,305
-6,912
-84% -$235K ﹤0.01% 2421
2023
Q4 		$332K Buy
8,217
+6,231
+314% +$187K ﹤0.01% 1700
2023
Q3 		$52.4K Sell
1,986
-12,173
-86% -$345K ﹤0.01% 2514
2023
Q2 		$244K Buy
14,159
+9,771
+223% +$147K 0.01% 1417
2023
Q1 		$72K Sell
4,388
-2,096
-32% -$24.4K ﹤0.01% 2170
2022
Q4 		$50K Sell
6,484
-10,311
-61% -$98.7K ﹤0.01% 2346
2022
Q3 		$167K Sell
16,795
-16,018
-49% -$166K ﹤0.01% 2096
2022
Q2 		$298K Buy
32,813
+15,247
+87% +$128K 0.01% 1486
2022
Q1 		$179K Buy
17,566
+1,050
+6% +$10.8K ﹤0.01% 1812
2021
Q4 		$275K Buy
16,516
+4,684
+40% +$198K ﹤0.01% 1531
2021
Q3 		$554K Buy
11,832
+6,485
+121% +$348K 0.01% 913
2021
Q2 		$326K Sell
5,347
-2,232
-29% -$127K 0.01% 1526
2021
Q1 		$467K Buy
7,579
+5,105
+206% +$334K 0.01% 1294
2020
Q4 		$176K Sell
2,474
-897
-27% -$43.3K 0.01% 1819
2020
Q3 		$127K Sell
3,371
-20,405
-86% -$642K ﹤0.01% 2946
2020
Q2 		$775K Buy
+23,776
New +$724K 0.03% 685
2020
Q1 		– Sell
-1,097
Closed -$38K – 3047
2019
Q4 		$38K Buy
1,097
+634
+137% +$17.6K ﹤0.01% 1504
2019
Q3 		$10K Buy
+463
New +$12.8K ﹤0.01% 2913

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Tower Research Capital (TRC)'s BBIO Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its BridgeBio Pharma (BBIO) stake by 166% in Q2 2026, buying an estimated $1.67M and bringing the position to 38,206 shares worth $2.85M. The position accounts for 0.07% of the portfolio, ranked #246.

Tower Research Capital (TRC) first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Tower Research Capital (TRC) held 38,206 shares of BridgeBio Pharma worth $2.85M as of Q2 2026.
  • Tower Research Capital (TRC) bought 23,857 BridgeBio Pharma shares in Q2 2026, an estimated $1.67M.
  • BridgeBio Pharma made up 0.07% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #246 holding.
  • Tower Research Capital (TRC) first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.